Phase 3 Clinical Trials With Primary Completion Dates in April 2018
This is a list of Phase 3 trials with primary completion dates in April 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|BCRX||BioCryst Pharmaceuticals, Inc.||2018-04-01||Phase 3||NCT02635724||Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza|
|BCRX||BioCryst Pharmaceuticals, Inc.||2018-04-01||Phase 3||NCT02369159||Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza|
|CBPO||China Biologic Products Holdings, Inc.||2018-04-01||Phase 3||NCT01979900||Phase III Clinical Study of Efficacy and Safety of Vaccaeâ¢ to Prevent Tuberculosis|
|KMPH||KemPharm, Inc.||2018-04-01||Phase 3||NCT03292952||KP415 Classroom Study in Children (6-12 Years of Age) With ADHD|
|REPH||Recro Pharma, Inc.||2018-04-01||Phase 3||NCT03323385||Evaluation of Preoperative N1539 in Colorectal Surgery|
|RIGL||Rigel Pharmaceuticals, Inc.||2018-04-01||Phase 3||NCT02077192||Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|